Display options
Cite
Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. 2011;6(3):359-369doi: 10.1586/eem.11.25.
Daniel, A. R., Hagan, C. R., & Lange, C. A. (2011). Progesterone receptor action: defining a role in breast cancer. Expert review of endocrinology & metabolism, 6(3), 359-369. https://doi.org/10.1586/eem.11.25
Daniel, Andrea R, et al. "Progesterone receptor action: defining a role in breast cancer." Expert review of endocrinology & metabolism vol. 6,3 (2011): 359-369. doi: https://doi.org/10.1586/eem.11.25
Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. 2011 May 01;6(3):359-369. doi: 10.1586/eem.11.25. PMID: 21857868; PMCID: PMC3156468.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Endocrinol Metab. 2011 May 01;6(3):359-369. doi: 10.1586/eem.11.25.

Progesterone receptor action: defining a role in breast cancer.

Expert review of endocrinology & metabolism

Andrea R Daniel, Christy R Hagan, Carol A Lange

Affiliations

  1. Departments of Medicine (Division of Hematology, Oncology and Transplantation) and Pharmacology, and The Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

PMID: 21857868 PMCID: PMC3156468 DOI: 10.1586/eem.11.25

Abstract

The ovarian steroid hormones, estradiol and progesterone, and their nuclear receptors (estrogen receptor [ER] and progesterone receptor [PR]), are involved in breast cancer development. As ER-positive/PR-positive tumors progress, they are likely to become steroid hormone-resistant/independent, yet often retain expression of their steroid receptors. Notably, up to 40% of women with steroid receptor-positive tumors exhibit de novo resistance or eventually fail on estrogen- or ERα-blocking therapies (acquired resistance). Indeed, most of the research on this topic has centered on mechanisms of ER 'escape' from endocrine therapy and the design of better ER-blocking strategies; signaling pathways that mediate endocrine (i.e., anti-estrogen) resistance are also excellent therapeutic targets. However, serious consideration of PR isoforms as important drivers of early breast cancer progression and ER modulators is timely and significant. Indeed, progress has been hindered by ER-centric experimental approaches. This article will focus on defining a role for PR in breast cancer with hopes of providing a refreshing PR-focused perspective.

References

  1. Development. 2005 Feb;132(4):681-7 - PubMed
  2. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5774-9 - PubMed
  3. Endocr Relat Cancer. 2004 Dec;11(4):643-58 - PubMed
  4. Mol Endocrinol. 2006 Apr;20(4):764-75 - PubMed
  5. Mol Cell Biol. 2004 Dec;24(24):10542-57 - PubMed
  6. Mol Endocrinol. 2003 Mar;17(3):309-17 - PubMed
  7. Endocr Rev. 1997 Aug;18(4):502-19 - PubMed
  8. J Clin Invest. 2007 Aug;117(8):2205-15 - PubMed
  9. Cell. 2000 Sep 29;103(1):41-50 - PubMed
  10. Breast Cancer Res. 2002;4(5):197-201 - PubMed
  11. Cancer Prev Res (Phila). 2011 Mar;4(3):414-24 - PubMed
  12. Nature. 2010 Jun 10;465(7299):803-7 - PubMed
  13. Genes Dev. 2000 Mar 15;14(6):650-4 - PubMed
  14. Cancer Res. 1997 Nov 15;57(22):4987-91 - PubMed
  15. Mol Endocrinol. 2000 Mar;14(3):359-68 - PubMed
  16. Endocrinology. 2007 Jun;148(6):2723-36 - PubMed
  17. Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 - PubMed
  18. Mol Cell Biol. 2005 Jan;25(1):264-77 - PubMed
  19. Stem Cell Rev. 2007 Jun;3(2):147-56 - PubMed
  20. J Biol Chem. 1998 Nov 20;273(47):31317-26 - PubMed
  21. Cancer Res. 2008 Feb 1;68(3):826-33 - PubMed
  22. Adv Exp Med Biol. 2008;630:94-111 - PubMed
  23. Lancet. 2003 Aug 9;362(9382):419-27 - PubMed
  24. Endocrinology. 2009 Jul;150(7):3318-26 - PubMed
  25. JAMA. 2002 Jul 17;288(3):321-33 - PubMed
  26. Womens Health (Lond). 2008 Mar;4(2):151-62 - PubMed
  27. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2989-94 - PubMed
  28. Mol Cell Endocrinol. 2009 Sep 24;308(1-2):47-52 - PubMed
  29. J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15 - PubMed
  30. Breast Cancer Res. 2011 Jan 28;13(1):302 - PubMed
  31. JAMA. 2010 Oct 20;304(15):1684-92 - PubMed
  32. J Clin Oncol. 2005 Oct 20;23(30):7721-35 - PubMed
  33. Cell Prolif. 2005 Dec;38(6):375-86 - PubMed
  34. Breast Cancer Res Treat. 2002 Mar;72(2):163-72 - PubMed
  35. Mol Endocrinol. 2008 Apr;22(4):823-37 - PubMed
  36. Mol Endocrinol. 2007 Dec;21(12):2890-906 - PubMed
  37. J Clin Oncol. 2006 Nov 20;24(33):e49-50 - PubMed
  38. Mol Cell Biol. 2011 Jun;31(12):2439-52 - PubMed
  39. J Biol Chem. 2002 Feb 15;277(7):5209-18 - PubMed
  40. J Natl Cancer Inst. 2006 Jul 19;98(14):1011-4 - PubMed
  41. J Biol Chem. 2002 Sep 13;277(37):33950-6 - PubMed
  42. Mol Cell. 2001 Aug;8(2):269-80 - PubMed
  43. Eur J Cancer. 1999 Feb;35(2):214-8 - PubMed
  44. Mol Cell Biol. 2003 Mar;23(6):1994-2008 - PubMed
  45. Endocrinology. 2009 May;150(5):2036-45 - PubMed
  46. J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 - PubMed
  47. Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a003178 - PubMed
  48. Mol Cell Biol. 2010 Jul;30(13):3249-61 - PubMed
  49. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5076-81 - PubMed
  50. Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1032-7 - PubMed
  51. Breast Cancer Res. 2008;10(5):R90 - PubMed
  52. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):509-14 - PubMed
  53. Cancer Res. 2004 Dec 15;64(24):9199-208 - PubMed
  54. J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):257-68 - PubMed
  55. Cancer Res. 1995 Nov 1;55(21):5063-8 - PubMed
  56. Mol Endocrinol. 2010 Nov;24(11):2126-38 - PubMed
  57. Crit Rev Eukaryot Gene Expr. 2008;18(1):11-33 - PubMed
  58. Mol Cell Biol. 2010 Dec;30(23):5456-72 - PubMed
  59. Endocrinology. 2005 Nov;146(11):4917-25 - PubMed
  60. J Clin Oncol. 1996 Oct;14(10):2709-12 - PubMed
  61. Nature. 2010 Nov 4;468(7320):98-102 - PubMed
  62. Mol Cell Biol. 2001 Sep;21(18):6122-31 - PubMed
  63. J Natl Cancer Inst. 2000 Feb 16;92(4):328-32 - PubMed
  64. J Clin Endocrinol Metab. 2008 Sep;93(9):3295-8 - PubMed
  65. Breast Cancer Res. 2004;6(6):R605-15 - PubMed
  66. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3799-804 - PubMed
  67. Biofactors. 2009 Nov-Dec;35(6):528-36 - PubMed
  68. Mol Endocrinol. 1997 Oct;11(11):1593-607 - PubMed
  69. Mol Endocrinol. 2003 Apr;17(4):575-88 - PubMed
  70. J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):19-27 - PubMed
  71. Endocr Relat Cancer. 2009 Jun;16(2):333-50 - PubMed
  72. Cancer Res. 1999 Sep 1;59(17):4276-84 - PubMed
  73. Breast Cancer Res Treat. 1999 Feb;53(3):217-27 - PubMed
  74. Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14287-92 - PubMed
  75. Mol Cell Biol. 2007 Jan;27(2):466-80 - PubMed
  76. J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):279-88 - PubMed
  77. Cell Prolif. 2003 Oct;36 Suppl 1:59-72 - PubMed
  78. Mol Cell Biol. 2005 Jun;25(12):4826-40 - PubMed
  79. DNA Cell Biol. 2003 Oct;22(10):633-40 - PubMed
  80. Medicina (B Aires). 2010;70(6):529-32 - PubMed
  81. J Biol Chem. 2001 Mar 16;276(11):8475-83 - PubMed
  82. Nature. 2010 Nov 4;468(7320):103-7 - PubMed
  83. Mol Endocrinol. 1997 Jun;11(6):823-32 - PubMed
  84. Science. 2006 Dec 1;314(5804):1467-70 - PubMed
  85. Biochem Biophys Res Commun. 2000 Nov 2;277(3):650-4 - PubMed
  86. Nature. 2006 Jan 5;439(7072):84-8 - PubMed
  87. Int J Cancer. 2006 Mar 1;118(5):1285-91 - PubMed
  88. Endocr Relat Cancer. 2009 Mar;16(1):85-98 - PubMed
  89. J Biol Chem. 1998 Apr 24;273(17):10696-701 - PubMed
  90. Cell. 1995 Aug 25;82(4):621-30 - PubMed
  91. J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61 - PubMed
  92. Cell. 1988 Oct 21;55(2):361-9 - PubMed
  93. Dev Cell. 2001 Oct;1(4):467-75 - PubMed
  94. Breast Cancer Res. 2006;8(4):R49 - PubMed
  95. EMBO J. 1998 Apr 1;17(7):2008-18 - PubMed

Publication Types

Grant support